Pearl River Capital’s Core Laboratories CLB Stock Holding History

Pearl River Capital’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,402	Closed	-$203K	–	545
2019 Q4	$203K	Buy	+5,402	New	+$243K	0.08%	477

Other funds holding CLB

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pearl River Capital's CLB Position: Q1 2020 in Review

Pearl River Capital sold out of Core Laboratories (CLB) in Q1 2020, closing a stake of 5,402 shares — an estimated $203K sold.

Pearl River Capital first reported a position in CLB in Q4 2019 and held it in 1 quarter. The position peaked at $203K in Q4 2019. 207 funds tracked by Wall St. Rank hold CLB as of Q1 2020.

Pearl River Capital reported no remaining Core Laboratories position as of Q1 2020 after selling out during the quarter.
Pearl River Capital sold 5,402 Core Laboratories shares in Q1 2020, an estimated $203K.
Pearl River Capital first reported a position in Core Laboratories in Q4 2019 and held it in 1 quarter.
Pearl River Capital's Core Laboratories position peaked at $203K in Q4 2019.
207 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2020.

Based on Pearl River Capital's 13F filing for Q1 2020, filed 6 May 2020.